Semiconductor photocatalysis to engineering deuterated N-alkyl pharmaceuticals enabled by synergistic activation of water and alkanols

Zhaofei Zhang\textsuperscript{1,5}, Chuntian Qiu\textsuperscript{1,5}, Yangsen Xu\textsuperscript{1}, Qing Han\textsuperscript{2,3}, Junwang Tang\textsuperscript{2}, Kian Ping Loh\textsuperscript{4} & Chenliang Su\textsuperscript{1}\textsuperscript{✉}

Precisely controlled deuterium labeling at specific sites of N-alkyl drugs is crucial in drug-development as over 50% of the top-selling drugs contain N-alkyl groups, in which it is very challenging to selectively replace protons with deuterium atoms. With the goal of achieving controllable isotope-labeling in N-alkylated amines, we herein rationally design photocatalytic water-splitting to furnish [H] or [D] and isotope alkanol-oxidation by photoexcited electron-hole pairs on a polymeric semiconductor. The controlled installation of $N$-CH\textsubscript{3}, -CDH\textsubscript{2}, -CD\textsubscript{2}H, -CD\textsubscript{3}, and $^{13}$CH\textsubscript{3} groups into pharmaceutical amines thus has been demonstrated by tuning isotopic water and methanol. More than 50 examples with a wide range of functionalities are presented, demonstrating the universal applicability and mildness of this strategy. Gram-scale production has been realized, paving the way for the practical photosynthesis of pharmaceuticals.
isotope labeling plays vital roles in various fields in synthetic chemistry, quantitative LC–MS/MS analysis, and the life sciences. The higher stability of C–D bonds than C–H bonds because of the deuterium kinetic isotope effect (DKIE) motivates the need for a “deuterium switch” in drug synthesis to improve biological properties, such as pharmacokinetics, pharmacodynamics (PK/PD), and metabolic stability. In 2017, the first deuterium-labeled drug, deutetrabenazine, was approved by the FDA and initiated a new era of deuterated clinical drug development. Among the myriad of commercial drugs, over 50% of the top sellers contain N-alkyl amine units, and the N-dealkylation metabolized cytochrome P450 (CYP450) are commonly found in such N-alkyl drugs and other bioactive molecules. Thus, deuterium substitution of N-alkyl groups in N-alkyl drug molecules could contribute to slow down the N–C bond cleavage, and impacts their pharmacodynamic properties and improve pesticide effects. In this regard, the precision synthesis of drug analogs with deuterated N-alkyl amine units holds great promise and has been attracting increasing interest.

Traditional approaches to N-alkyl drugs usually require the use of deuterated alkylation reagents such as CD₃I. Reduction of N-CO₂R moieties with LiAlD₄ is another effective approach that has good potential for the introduction of N-CD₃ group without formation of ammonium salts. However, introduction of extra functional group, use of hazardous and strong reducing reagent, and poor functionality tolerance limit its practical application. Recently, catalytic hydrogen isotope exchange (HIE) of α- or β- amines has been emerged as a promising way to incorporate stable deuterium labels in organic molecules. This method enables the isotopic labeling of complex organic compounds with high efficiency and selectivity. The mechanism involves the use of a semiconductor photocatalyst in the presence of water and deuterated water. The reaction proceeds under light irradiation, where the photocatalyst facilitates the separation of electron-hole pairs. The photoexcited electrons reduce the deuterated water, while the holes oxidize the functional groups. The result is the incorporation of deuterium labels into the desired molecules. This technique offers a cleaner and more efficient method for isotopic labeling compared to traditional chemical methods, making it a valuable tool in drug discovery and development.
multi-deuterium or tritium atoms into N-alkyl amine-based drugs (Supplementary Fig. 2b). For example, MacMillan group 52 reported a powerful photo-redox mediated HIE reaction which could efficiently and selectively install deuterium or tritium at α-amino sp² C–H bonds of the N-alkyl amine-based drug molecules. In this protocol, the α-position of amines is oxidized by a molecular photocatalyst to yield α-amino radical, which was then trapped by the hydrogen atom transfer (HAT) catalysis mediated the abstraction of deuterium from D₂O or T₂O to furnish α-deuterated or tritiated amine product. Multi-deuterium atoms incorporation at all α-position of pharmaceutical amines (more than 4.0 deuteriums per molecule) with a wide range of D-incorporation ratio (from 1 to 91%) is generally occurred. Still, the development of a general and mild method for the substitution of the traditional deuterated alklylation from toxic deuterated reagents like CD₃I is in high demand to effectively and selectively functionalize pharmaceutical amines. Further, the precise control of deuterium atoms number at the α-position of N-alkyl drugs with high deuterium incorporation currently remain unexplored, while it is particularly attractive for their potential use in mechanistic and metabolic studies. 44-45

Semiconductor photocatalysts, which provide redox center on the surface upon light irradiation can be designed to decompose H₂O/D₂O to furnish reductive [H]/[D] and simultaneously oxidize organic molecules by the photoexcited electron–hole pairs. Synergistic utilization of those reductive [H]/[D] and reactive organic species holds great potential for production of deuterated chemicals and pharmaceuticals, e.g. D-labeling N-alkyl pharmaceuticals, from isotopic water and organics. Polymeric carbon nitride (PCN) is a nontoxic, highly stable, low-cost, and scalable polymer semiconductor with a suitable redox window (from approximately +1.2 V vs. saturated calomel electrode (SCE)) 46-51. These characteristics define PCN as an ideal semiconductor photocatalyst for effective water splitting coupled with controlled oxidation by photoexcited electron–hole pairs. Herein, we utilize highly crystalline PCN as a semiconductor photocatalyst for the sustainable synthesis of N-alkyl chemicals and drugs with well-controlled isotopic labeling. 52 Upon visible-light irradiation, electron–hole pairs are generated on crystalline PCN. Photogenerated electrons are transferred to the anchored Pd nanoparticles and utilized to reduce water to furnish absorbed [H]/[D] species. Meanwhile, photogenerated holes with appropriate oxidative ability are designed to selectively oxidize isotopic alkanols, furnishing isotopic aldehydes for aldehyde-amine condensation to produce imine intermediates. These imines are subsequently reduced by [H]/[D] from water splitting, producing corresponding N-alkyl chemicals and drugs (Fig. 1b). Compared to traditional approaches from deuterated alkylation reagents, this photocatalytic strategy exhibits several advantages: (a) the low-cost and sustainable isotopic water and alkanol is proposed as a combined deuterated alklylation reagent, (b) benefiting from this unique design, precise controlling the number of deuterium atoms (i.e., N-CD₃, CD₂H and CDH₂) at the metabolic position of N-Me drugs is enabled by simply tuning the isotopic water and methanol (Fig. 1c); (c) excess deuterated methylation leading to ammonium salts could be effectively avoided; (d) finally, this heterogeneous process exhibits high yields, broad reaction scope, excellent one-step D-incorporation, and scalable production, thus paving the way towards deuterated drug studies and developments.

Results
Controllable installation of N-CD₃ groups of p-toluidines and diphenylamines. We started our investigation by screening conditions for the water-splitting-based N-methylation of amines using highly crystalline PCN (PCPN) as the semiconductor photocatalyst 53, water and methanol as the green methylating reagents, and p-toluidine as the amine. The optimized conditions are summarized in Supplementary Table 1, where the N-methylation product of p-toluidine, N,N-(CH₃)₂ p-toluidine, was obtained in 94% yield. Using the optimized conditions, isotopic water and methanol were used to investigate the synthesis of deuterated compounds and the reaction pathway. Generally, multiple reaction processes are required to achieve high deuteration content in the production of deuterated chemicals and pharmaceuticals. Here, the use of D₂O and CD₃OD afforded N,N-(CD₃)₂ p-toluidine in 89% yield with high D incorporation (97%). To trace the deuterium source, H₂O/CD₃OD was used, which afforded N,N-(CD₂H)₂ p-toluidine in 91% yield, with nearly quantitative D-incorporation (99%). The obtained partially deuterium-labeled product suggests that CD₃OH/CD₃OD are probably oxidized to [D₃C=O] by photogenerated holes, which is consistent with the mechanism of photocatalytic water splitting using methanol as the sacrificial agent. 48,49 Aldehyde-amine condensation of [D₃C=O] and p-toluidine occurs to furnish imine intermediates for sequential hydrogenation by reductive [H] from water splitting (Fig. 1c). The secondary amine intermediate then undergoes another aldehyde-amine condensation followed by hydrogenation with [H], producing the corresponding N,N-(CD₃H)₂ p-toluidine product. Consistent with the aforementioned reaction pathway, using the D₂O/CH₃OD system could introduce N-CD₃H groups (91%) with high D content (>99%). The controllable D-labeled N-alklylation of secondary amines was also examined, affording N-CH₃ -CD₃, -CD₂H, and -CDH₂ diphenylamines in high yields (74–94% yields) with excellent D incorporation (>97%) (Fig. 2). Our results show

Fig. 2 Controllable D-labeled N-methylation of primary and secondary amines. Y refers to isolated yields of deuterated products. D refers to D-incorporation percentages based on the calculation of ¹H-NMR.
convincingly that the number of deuterium atoms installed at the N-methyl groups can be precisely controlled, thus showing great promise for the precise introduction of deuterium atoms in the specific position of N-Me-based drugs.

**Photocatalytic water-splitting-based N-methylation of amines.**

Next, the generality of the water-splitting-based N-trideuteromethylation of amines was tested by synthesizing valuable N-CD$_3$-based deuterated chemicals and pharmaceutical derivatives (Fig. 3). Primary amines underwent two N-trideuteromethylation reactions, providing products with $N,N'$-(CD$_3$)$_2$ units with excellent D incorporation (97–99%) (Fig. 3, 3aa-3af). The use of aniline substrates bearing both electron-donating groups (p-Me, p-OMe) and electron-withdrawing groups (p-CN, p-Cl) produced the corresponding $N,N'$-(CD$_3$)$_2$-anilines in 69–89% yields (3aa-3ad). Sensitive substrates with alkyl chiral centers (3ac and 3af) were compatible and unperturbed. Since most N-alkyl drugs are fabricated from secondary amines via N-alkylation reactions, the N-trideuteromethylation of secondary amines was investigated with great interest. To our delight, this protocol with secondary amines exhibits a broad reaction scope, good functional group tolerance and excellent D incorporation. N-alkyl anilines, including substituted N-Me anilines and N-Bn anilines, furnished the corresponding products with high D incorporation (91–98%) and in excellent yields (84–94%). N-trideuteromethylation of ethyl phenylglycinate (3bg), a representative amino acid derivative, as well as estrone derivate (3bi) was achieved, attesting to the ability to deuterate bioactive molecules. For the diamine substrate 3bh, di-CD$_3$ was simultaneously introduced in 71% yield. This protocol was also applicable to a wide range of diary amines bearing substituted phenyl (3ca-3ce), naphthyl (3cf), and phenylglycinate (3eh), and pharmaceutical units such as chlorambucil (3ci), oxaprozin (3cj), and (R)-naproxen (3ck). A steric effect-controlled highly chemoselective N-trideuteromethylation of diary amines is observed (3cl). The N-CD$_3$ incorporation of heterocyclic amines such as indoline...
and iminodibenzyl was achieved successfully. These heterocyclic skeletons are widespread in natural products, pharmaceuticals and key intermediates. Aliphatic amines were also found to be competent substrates, providing the desired products (3da–3dh) in good yields. Finally, the strategy could be extended to the N-deuterated alkylation of amines by replacing d5-methanol with other deuterated alkanols, such as d5-ethanol for N-CD2CD3 incorporation (3e). This protocol exhibits highly efficient in production of deuterated N-alkyl chemicals with excellent D-incorporation, thus holding great potential application towards the synthesis of stable isotope-labeled compounds for synthetic mechanism study as well as LC/MS quantification.

**Sustainable synthesis of deuterated pharmaceuticals.** N-Me amine units are present in many of the 200 top-selling drugs produced in 2018 and are often required for their intended pharmacological functionality. Deuterium substitution of the N-Me groups of these drugs is highly desired. We tested the protocol developed above for the synthesis of N-CD2-based pharmaceuticals and bioactive molecules (Fig. 4). Here, the use of heterogeneous catalyst provides an ideal solution to avoiding poising these drugs from the molecular catalyst due to its easy removal. First, late-stage functionalization of drug molecules with primary and secondary amines was evaluated. Di-N-trideutermethylation of flutamide and nimesulide was accomplished, providing the deuterated drug derivatives in good yields (71–80% yields) without affecting the amide and sulfamine functionalities. A variety of commercially available pharmaceuticals with secondary amine units, namely, fluoxetine, tetracaine, atomoxetine, sertraline, paroxetine and vortioxetine, smoothly underwent N-trideutermethylation (4c–4h, 60–94% yields), reconfirming the universality of our strategy. More importantly, this mild and general process enables access to site-specifically labeled drugs in a single step. Deuterium-labeled analogs of butenafine could be obtained in 67% yield (4k). Trideutermethylation of monomethylated disipramine and amoxapine gave imipramine-d3 (4i, 92%) and loxapine-d3 (4j, 94%), respectively. The use of C5D5N/OD/D2O as an alkylation reagent successfully afforded alverine-d3 (4l) in high yield (84%). In addition, synthesis of dofetilide-d3 was achieved in four steps with 32% overall yields from low-cost and commercially available starting materials. Gram-scale syntheses of both loxapine-d3 and dofetilide-d3 with high yields were demonstrated, highlighting the practical utility of this protocol. Again, all D-labeled pharmaceuticals and their analogs gave excellent deuterium incorporation.

Isotope-labeled bioactive compounds are extensively used to study interactions with lipid membranes, proteins, nucleic acids, etc. In particular, the controllable incorporation of partially

---

**Fig. 4 Late-stage functionalization and preparation of deuterated drugs.** a Late-stage functionalization of drug molecules. b Production of deuterated drugs. c Gram-scale synthesis of dofetilide-d3.
deuterium-labeled N-methyl groups (CDH₂, CD₂H, or CD₃) slows drug metabolism to improve the pesticide effect. However, their synthesis remains a great challenge. Our controllable deuterium-labeling strategy was successfully applied for the facile synthesis of N-CD₃, N-CD₂H and N-CDH₂ nimesulide derivatives (4b, 4o and 4p), butenafines-d₂, d₃ and d₄ (4k, 4r and 4s),loxapines-d₁, d₂ and d₃ (4j, 4u and 4v) and imipramines-d₅, d₆ and d₇ (4i, 4x and 4y) with high yields and uniformly high D incorporation (>95%) (Fig. 5). In all these drugs, only the target N-alkyl units were specifically labeled with deuterium. ¹³C-labeled drugs are of significant importance in medical biology for tracking metabolites and quantitative analysis by mass spectrometry and ¹³C NMR spectroscopy. This protocol can also be applied for the sustainable synthesis of ¹³C-labeled drugs by replacing methanol with ¹³CH₃OH. As expected, ¹³C-labeled nimesulide derivative (4q), butenafine (4t),loxapine (4w) and imipramine (4z) were readily obtained with comparable yields.

In summary, a powerful semiconductor photocatalytic system for the sustainable and scalable construction of deuterated pharmaceuticals and chemicals has been discovered. This strategy is characterized by high yields, excellent D incorporation in a single step, the use of low-cost and sustainable deuterated methylating reagents (isotopic water and methanol), excellent functional group tolerance including a range of pharmaceutically relevant functionalities, and mild conditions. Significantly, the unique controllable D-labeling protocol provides the ability to precisely control the number of deuterium atoms (i.e., N-CD₃, CD₂H and CDH₂) at the metabolic position of pharmaceuticals, which is critically important for deuterated drug discovery.

Finally, the present results reveal a new horizon of photosynthesis for direct pharmaceutical production.

**Methods**

**Synthesis of CPCN and Pd/CPCN photocatalyst.** In a typical synthesis, melamine (3.0 g, Alfa Aesar) was ground with KBr (2.0 g, Alfa Aesar). Then, the resultant mixture was heated to 350 °C for 3 h in a tube furnace. After cooling to room temperature, the bright yellow-green product was washed with boiling deionized water several times and collected by filtration, followed by drying at 60 °C under vacuum. As-prepared sample is denoted as CPCN. Pd/CPCN photocatalyst was prepared by photodeposition process. In brief, as-synthesized CPCN (0.3 g) was dispersed in a mixture with 80 mL deionized water and 20 mL glycol. After ultrasonication treatment for 3 h, 0.01 M H₂PdCl₄ was added into the mixture, and then the mixture was treated under 300 W Xe lamp illumination for 1 h to reduce Pd²⁺. The brownish slurry was centrifuged and washed with deionized water for three times. After dried in an oven at 70 °C overnight under vacuum condition, as-prepared sample denoted as Pd/CPCN were obtained.

**Photocatalytic deuterated N-methylation reaction.** Typically, 25 mg of Pd/CPCN and 0.4 mmol of substrate and AlCl₃ (0.3 mmol) were dispersed in a mixture solution with Acetonitrile/D₂O/CD₃OD = 2 ml/1.5 ml/1.0 ml, and then sonicated for 1 min. The reaction mixture was then irradiated with a LED lamp (20 W, λ = 420 nm, Suncat instruments Co., Ltd., Beijing, China) for 4-24 h under Ar 25°C by using a flow of cooling water during the reaction. After reaction, the mixture was centrifuged to remove photocatalyst. The supernatant was extracted by adding 5 mL of CH₂Cl₂. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel to furnish the corresponding product. The isolated yield was calculated by dividing the amount of the obtained desired product. Deuterium incorporation were checked and calculated by NMR.

**Characterization equipment.** The crystal structure of catalyst was characterized by X-ray diffraction (XRD) (Ultima IV, Rigaku) at 40 kV and 40 mA (Cu Ka X-ray radiation source) with a scanning speed and step interval of 4° min⁻¹ and 0.01°, respectively. Transmission electron microscope (TEM) images were obtained using...
a HT7700 TEM (Hitach). The solid diffuse reflectance spectra (DRS) were collected on a UV–Vis–NIR spectrophotometer (Cary 5000, Varian). NMR tests were conducted on Bruker AVANCE III NMR spectrometer (500 and 600 MHz). The high-performance mass spectrometry was conducted by a Q Exactive GC Orbitrap GC-MS/MS (Thermo Scientific).

**Data availability**

All data are available from the authors upon reasonable request.

Received: 3 April 2020; Accepted: 11 August 2020; Published online: 18 September 2020

**References**

1. Belleau, B.; Burba, J.; Pindell, M. & Reifenstein, J. Effect of deuterium substitution in sympathomimetic amines on adrenergic responses. *Science* **133**, 102–104 (1961).

2. Gaffney, T. E.; Hammar, C. G.; Holmstedt, B. & McMahon, R. E. Ion speciation conducted on Bruker AVANCE III NMR spectrometer (500 and 600 MHz). The high-performance mass spectrometry was conducted by a Q Exactive GC Orbitrap GC-MS/MS (Thermo Scientific).

3. Simmons, E. M. & Hartwig, J. F. On the interpretation of deuterium kinetic isotope effects in C–H bond functionalizations by transition-metal complexes. *Angew. Chem. Int. Ed.* **51**, 3066–3072 (2012).

4. Atzrodt, J.; Derradu, V.; Kerr, W. J. & Reid, M. Deuterium- and tritium-labelled compounds: applications in the life sciences. *Angew. Chem. Int. Ed.* **15**, 10397–10404 (2009).

5. Elmore, C. S. In *Reports on Medicinal Chemistry Vol. 44* (ed. Macor, J. E.) 515–534 (Academic Press, 2009).

6. Allen, P. H. M.; Hickey, J.; Kingston, L. P. & Wilkinson, D. J. Metal-catalysed isotopic exchange labelling: 30 years of experience in pharmaceutical R&D. *J. Label Compd. Radiopharm.* **53**, 731–738 (2010).

7. Gant, T. G. Using deuterium in drug discovery: leaving the label in the drug. *J. Med. Chem.* **57**, 3595–3611 (2014).

8. Mullard, A. Deuterated drugs draw heavier backing. *Nat. Rev. Drug Discov.* **15**, 219–221 (2016).

9. Pirali, T.; Serafini, M.; Cargnin, S. & Genazzani, A. A. Applications of deuterium in medicinal chemistry. *J. Med. Chem.* **62**, 5276–5297 (2019).

10. Mullard, A. FDA approves first drug for primary progressive multiple sclerosis. *Nat. Rev. Drug Discov.* **16**, 305–307 (2017).

11. McGrath, N.; Brichacek, A. M. & Njardarson, J. T. A graphical journey of first drug for primary progressive multiple sclerosis. *Lancet. Respir. Med.* **5**, 192 (2017).

12. Geng, H. et al. Practical synthesis of C1 deuterated aldehydes enabled by NHC catalysis. *Nat. Cat.* **2**, 1071–1077 (2019).

13. Liu, W. et al. Mesoionic carbene (MIC)-catalyzed H/D exchange at formyl groups. *Chem. 5*, 2484–2494 (2019).

14. Jus, E. M.; Elmore, C. S.; Nilsson, G. N.; Thompson, R. A. & Weidolf, L. Use of radiolabelled compounds in drug metabolism and pharmacokinetic studies. *Chem. Res. Toxicol.* **25**, 532–542 (2012).

15. Nelson, S. D. & Trager, W. F. The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalysed reactions, and mechanisms of metabolically dependent toxicity. *Drug Metab. Dispos.* **31**, 1481–1498 (2003).

16. Dogutan, D. K. & Nocera, D. G. Artificial photosynthesis at efficiencies greatly exceeding that of natural photosynthesis. *Acc. Chem. Res.* **52**, 3143–3148 (2019).

17. Kisch, H. Semiconductor photocatalysis—mechanistic and synthetic aspects. *Angew. Chem. Int. Ed.* **52**, 812–847 (2013).

18. Kisch, H. Semiconductor photocatalysis for chemoselective radical coupling reactions. *Acc. Chem. Res.* **50**, 1002–1010 (2017).

19. Ghosh, I. et al. Organic semiconductor photocatalyst can biofunctionalize arenes and heteroarenes. *Science* **365**, 360–366 (2019).

20. Wang, X. et al. A metal-free polymeric photocatalyst for hydrogen production from water under visible light. *Nat. Mater.* **8**, 78–80 (2009).

21. Keidar, F. K. & Kisch, H. Functional carbon nitride materials—design strategies for electrochemical devices. *Nat. Rev. Mater.* **2**, 17030 (2017).

22. Qu, C. et al. Highly crystalline K-intercalated polymeric carbon nitride for visible-light photocatalytic alkenes and alkynes deuterations. *Adv. Sci.* **6**, 1800140–1800149 (2019).

23. Schönherr, H. & Cerni, T. Profound methyl effects in drug discovery and a call for new C-H methylations reactions. *Angew. Chem. Int. Ed.* **52**, 12256–12267 (2013).
54. Chatterjee, J., Gilon, C., Hoffman, A. & Kessler, H. N-methylation of peptides: a new perspective in medicinal chemistry. *Acc. Chem. Res.* 41, 1331–1342 (2008).
55. Barreiro, E. J., Kümmeler, A. E. & Fraga, C. A. M. The methylation effect in medicinal chemistry. *Chem. Rev.* 111, 5215–5246 (2011).
56. White, T. R. et al. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. *Nat. Chem. Biol.* 7, 810–817 (2011).
57. Chatterjee, J., Rechenmacher, F. & Kessler, H. N-methylation of peptides and proteins: an important element for modulating biological functions. *Angew. Chem. Int. Ed.* 52, 254–269 (2013).
58. Natte, K., Neumann, H., Beller, M. & Jagadeesh, R. V. Transition-metal-catalyzed utilization of methanol as a C1 source in organic synthesis. *Angew. Chem. Int. Ed.* 56, 6384–6394 (2017).
59. Cernak, T., Dykstra, K. D., Tyagarajan, S., Vachal, P. & Krska, S. W. The medicinal chemist’s toolbox for late stage functionalization of drug-like molecules. *Chem. Soc. Rev.* 45, 546–576 (2016).
60. Kitamura, K. et al. Synthesis of [N-13CH3] drugs (chlorpromazine, triflupromazine and promazine). *J. Label Compd. Radiopharm.* 43, 865–872 (2000).
61. Elmore, C. S. & Bragg, R. A. Isotope chemistry: a useful tool in the drug discovery arsenal. *Bioorg. Med. Chem. Lett.* 25, 167–171 (2015).
62. Syroeshkin, A. et al. D/H control of chemical kinetics in water solutions under low deuterium concentrations. *Chem. Eng. J.* 377, 119827 (2019).
63. Kitamura, K. et al. Dissociation constants of phenothiazine drugs incorporated in phosphatidylcholine bilayer of small unilamellar vesicles as determined by carbon-13 nuclear magnetic resonance spectrometric titration. *BBA Biomembranes* 61-67, 6394 (2017).
64. Li, Y., Sorribes, I., Yan, T., Junge, K. & Beller, M. Selective methylation of amines with carbon dioxide and H2. *Angew. Chem. Int. Ed.* 52, 12156–12160 (2013).

**Acknowledgements**
This work was financially supported by the National Natural Science Foundation of China (21972094, 21902105), China Postdoctoral Science Foundation (2019M653004), Guangdong Special Support Program, Pengcheng Scholar program, Shenzhen Peacock Plan (KQXSCX20170727100802505 and KQTD201605312042971), and Foundation for Distinguished Young Talents in Higher Education of Guangdong (2018QNCX221). K.P.L. acknowledge NRF-CRP grant “Two-Dimensional Covalent Organic Framework: Synthesis and Applications”. Grant number NRF-CRP16-2015-02, funded by National Research Foundation, Prime Minister’s Office, Singapore.

**Author contributions**
Z.Z. and C.Q. contributed equally to this work. C.S., Z.Z. and C.Q. designed this work. Y.X. and C.Q. synthesized and characterized the catalysts. Z.Z. and C.Q. optimized reaction conditions. Z.Z. accomplished the reactions and substrate scopes. Z.Z., C.Q., C.S., Q.H., J.T., and K.P.L. co-wrote the manuscript. C.S. supervised the research. All the authors discussed and commented on the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-020-18458-w.

**Correspondence** and requests for materials should be addressed to C.S.

**Peer review information** *Nature Communications* thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

**Reprints and permission information** is available at http://www.nature.com/reprints

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2020